Physician profile

Gregory Mark Singer

Cardiovascular Disease · Rochester, NY

NPI 1114010865

$84,842.40

in general payments reported to CMS, 2019-2025

10 companies · $255 in 2025

The $255 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$1,000.50
Food and Beverage$561.22

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Janssen Pharmaceuticals, INC $62,856.40 2019-2023 Xarelto
Amgen INC. $18,965.43 2019-2024 Repatha
Sanofi-Aventis U.S. LLC $1,190.16 2021-2023
E.R. Squibb & Sons, L.L.C. $713.32 2019-2024 Eliquis, Camzyos
Novartis Pharmaceuticals Corporation $462.56 2019-2023
Medtronic, INC. $282.09 2021-2025 In.Pact Admiral, Aurora Ev-Icd Mri Surescan, Linq II
Abbott Laboratories $166.13 2019
Welch Allyn $162.00 2021
Medtronic Vascular, INC. $31.73 2019-2020
Pfizer INC. $12.58 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Gregory Mark Singer

$84,842.40

in general payments reported 2019-2025

Years
2019-2025
Top company
Janssen Pharmaceuticals, INC
Context
The $255 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/186982/gregory-mark-singer

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.